Catheter-related Infections in Pediatric Patients Due to a Rare Pathogen: Herbaspirillum huttiense

• Published in: The Pediatric infectious disease journal Vol. 43; no. 7; pp. e231 - e234
• Main Authors: Özen, Seval, Kanik Yüksek, Saliha, Dinç, Bedia, Üçkardeş, Fatih, Konca, Hatice Kübra, Erat, Tuğba, Güney, Ahmet Yasin, Güneş, Ömer, Coşkun, Zehra Nihan, Gülhan, Belgin, Bayhan, Gülsüm İclal, Çöplü, Nilay, Parlakay, Asli Nur Özkaya, Özbek, Namik Yaşar
• Format: Journal Article
• Language: English
• Published: United States 01-07-2024
• ISSN: 0891-3668; 1532-0987; 1532-0987
• DOI: 10.1097/INF.0000000000004350

Herbaspirillum species are nonfermenting, aerobic, helical or curved, Gram-negative bacteria belonging to the class Betaproteobacteria, order Burkholderiales. To date, only a few studies have reported on the epidemiology, clinical symptoms, antibiotic susceptibility profiles, treatment and outcomes of Herbaspirillum huttiense -related infections in pediatric patients.
The aim of this study was to present 3 years of H.Huntiense data, antibiotic susceptibility profiles, systemic antibiotics and antibiotic lock therapy (ALT) options and clinical outcomes.
Fourteen episodes of infection in 12 patients were included in this retrospective study. The patients had a male/female ratio of 1:1 and a median age of 160.5 months (range, 3-198 months). Catheter-related bloodstream infection (CRBSI) was detected in 11 patients. Only 1 patient developed catheter-related infective endocarditis. The patient's catheter was removed, and she was successfully treated with systemic antibiotics for 4 weeks. Systemic antibiotics were used in all infections related to H. huttiense . In septic, critically ill patients, the catheter was removed, and systemic antibiotics were started. Port catheters were removed in 5 patients. ALT was performed in clinically stable patients. ALT using amikacin was administered to 6 patients through the port catheter. Two patients had a 2nd attack. After the 2nd ALT treatment, 1 patient cured, and the catheter of the other patient was removed due to persistent microbial growth in cultures. Antimicrobial susceptibility testing of the reported isolates showed susceptibility to meropenem (90%), ceftazidime (87%) and piperacillin/tazobactam (65%), with 92% resistance to colistin.
H. huttiense is an emerging pathogen in CRBSI. Piperacillin/tazobactam, ceftazidime and meropenem appear to be good therapeutic options for the treatment of H. huttiense infections. ALT and systemic antibiotics can be used in H. huttiense -CRBSI to sterilize and preserve the central venous catheter.